Endo News Roundup: Managing HbA1c & CV Risks
New studies highlight which T2DM meds help reduce CV risks and, for metformin failure, the benefits of early intervention & a promising drug combo.
T2DM patients who take gliptins or glitazones may have decreased risks of heart failure, cardiovascular disease, and all-cause mortality. Early intervention in T2DM patients who fail metformin monotherapy can lead to rapid attainment of HbA1c goals. Insulin glargine plus the glucose-lowering agent lixisenatide complement each other and lead to clinically meaningful HbA1c reductions in T2DM more than either drug alone.
Endo News Roundup: Managing HbA1c & CV Risks
Gliptins and Glitazones Decrease Cardiac Risks. Abstract link.
T2DM patients who take glitazones or gliptins alone or in combination tend to have lower CV risks.
Gliptins/glitazones study results
Intensify Therapy for Metformin Failures. Abstract link.
Intensification of therapy after metformin failure can help patients reach HbA1c goals.
Metformin therapy intensification study results
Two-Drug Combo Redules HbA1c in Metformin Failure. Abstract link.
A combination of insulin glargine and lixisenatide reduces HbA1c significantly more than either drug given separately in T2DM patients who are inadequately controlled on metformin.
Insulin glargine-lixisenatide study results
Take-home Messages
